Other Events ·
Sanofi halts clinical development of amlitelimab for atopic dermatitis citing lack of meaningful improvement over existing standards of care
SNYSanofi
Sanofi announced the discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis. The company decided not to submit the drug for global regulatory reviews because the current efficacy and safety evidence does not suggest it would provide a meaningful improvement over existing standards of care. Sanofi is not amending its full-year 2026 guidance due to this decision. Additionally, the company is evolving its Executive Committee effective September 1, 2026, to support its next strategic chapter. Sanofi is a biopharma company that develops medicines and vaccines.